The Europe Neurological Biomarkers Market would witness market growth of 13.7% CAGR during the forecast period (2022-2028).
With the recent development of neurological biomarkers found in blood, identifying and treating neurological diseases such as chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, autism, and major depressive disorder should become simpler. Recent developments in detection technology have made it possible to find neurological biomarkers in blood.
For instance, the Simoa (single-molecule array) technology from Quanterix increases sensitivity by digitizing the extremely effective ELISA (enzyme-linked immunosorbent test) method of measuring binding between two molecules. For the biomarker of interest, Quanterix screens patient samples using 720,000 microscopic beads covered with capture antibodies. The beads are then mixed with a fluorescent marker and spread out into 216,000 isolated microchambers.
The high signal-to-noise ratio results in very responsive detection. Numerous researchers use Quanterix's technology to evaluate biomarker quantities in both CSF and blood, with almost half of their current applications being related to neurology. One such is their work on CTE and concussion biomarkers. Mild concussions can cause brain damage without causing any symptoms, and the accumulation of multiple sub-concussive hits to the brain leads to the development of CTE.
Doctors in the UK informed the platforms of 153 unique instances that met the clinical case criteria during this time, which is comparable to the aggregate COVID-19 data from UK government public health organizations. Of the 153 patients, complete clinical data were available for 125 (82%) of them. In the UK, many people experience tinnitus, yet the illness is poorly understood and has no standard therapy. Tinnitus is thought to be brought on by aberrant nerve discharge patterns in the brain's hearing centers. These characteristics have led to a flourishing market for regional neurological biomarkers market.
The Germany market dominated the Europe Neurological Biomarkers Market by Country in 2021; thereby, achieving a market value of $822.7 Million by 2028. The UK market is experiencing a CAGR of 12.8% during (2022 - 2028). Additionally, The France market would showcase a CAGR of 14.5% during (2022 - 2028).
Based on Type, the market is segmented into Proteomic, Genomic, Metabolomic and Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Neurological Biomarkers Market will Hit $12.9 Billion by 2028, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.
By Type
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 